Publications by authors named "Vivek Subbiah"

Claim this Profile
I
Imperative of Comprehensive Molecular Profiling as Standard of Care for Patients With Rare Cancers.
Vivek Subbiah, Razelle Kurzrock

JCO Oncol Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of anti-cancer medicines in the current era.
Bradley J Monk, Manish R Patel, Sarper Toker, Vivek Subbiah, Lucio N Gordan

Cancer Treat Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Presentation of Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies.
Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, Daniel Luckett, Dan Schlauch, Vivek Subbiah

JCO Precis Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer treatment paradigms in the precision medicine era.
Vivek Subbiah, Giuseppe Curigliano, Jason K Sicklick, Shumei Kato, Kjetil Tasken

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer.
Mihaela Aldea, Julia K Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Vivek Subbiah

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review.
Vivek Subbiah, Razelle Kurzrock

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rethinking Cancer Drug Development through Tumor-agnostic Precision Medicine.
Vivek Subbiah

Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RadOncRAG: A Novel Retrieval-Augmented Generation Framework Improves Large Language Model Benchmark Performance in Radiation Oncology.
Nikhil Gautam Thaker, Navid Redjal, Adam Dicker, Arturo Loaiza-Bonilla, Trevor Royce, Vivek Subbiah

JCO Clin Cancer Inform· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1a/b Multi-Center Study of BPM31510IV Targeting Mitochondrial Metabolism/Warburg Effect as Monotherapy and Combination Chemotherapy in Solid Tumor Patients.
Vivek Subbiah, Peter P Yu, Rangaprasad Sarangarajan, Michael A Kiebish, Leonardo O Rodrigues

Cancer Res Commun· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers.
Steven H Lin, Vivek Subbiah, Shinya Neri, Evan N Cohen, Ziyi Li

Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical evaluation of the ProfiLER-02 study design and outcomes.
Vivek Subbiah, Razelle Kurzrock

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogate end points in oncology: aligning drug development incentives and patient needs.
Matthew Vogel, Rona Yaeger, David J Stewart, Vivek Subbiah, Frank S David

Nat Rev Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus.
Hampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, Emad Anwar Dawoud, Zine-Charaf Mohamed Amir, Vivek Subbiah

Future Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging tumour classification and treatment.
Vivek Subbiah, Benedikt Westphalen, Guiseppe Curigliano, Fabrice Andre

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer.
Edwin Lin, Ying-Chun Lo, Vivek Subbiah, Rajat Thawani, Aakash Desai

Exp Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras.
Vivek Subbiah, Megan Othus, Jim Palma, Branko Cuglievan, Razelle Kurzrock

Am Soc Clin Oncol Educ Book· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From dominance to decline: can we reverse the trend in small molecule and TKI cancer therapies?
Denis Horgan, Paul Hofman, Daniel Schneider, Umberto Malapelle, Vivek Subbiah

Pathologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim, Vivek Subbiah

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial.
Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A How, Justin Moyers, Vivek Subbiah

J Immunother Precis Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
Timothy Price, Iwona Lugowska, Sant P Chawla, Gerald Falchook, Vivek Subbiah

BMJ Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue-agnostic cancer therapies: promise, reality, and the path forward.
Vivek Subbiah

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies: A Pooled Analysis of Early-Phase Clinical Trials.
Rafael Grochot, Kroopa Joshi, Antonella Cammarota, Rachel Woodford, Gethini Sathanantham, Vivek Subbiah

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.
Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, Vadim Bernard-Gauthier, Milena Kurtinecz, Vivek Subbiah

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
David R Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner, Miles C Andrews, Vivek Subbiah

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz, Vivek Subbiah

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis